Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential

5. Arcellx, Inc. (NASDAQ:ACLX)

Upside Potential as of April 11: 106.76%

Duquesne Capital’s Stake Value: $5.68 million

Number of Hedge Fund Holders: 37

Arcellx Inc. (NASDAQ:ACLX) is a biotechnology company developing immunotherapies for cancer patients. The company focuses on cell therapy treatments, particularly for multiple myeloma and other incurable diseases. Its lead product candidate is anito-cel for treating relapsed or refractory multiple myeloma.

In Q4 2024, Arcellx Inc.’s (NASDAQ:ACLX) financials were muted. Collaboration revenue, the company’s primary income earner, decreased by $47.8 million to $15.3 million. However, the revenue for the full year 2024 only declined by $2.4 million to $107.9 million. Meanwhile, the company’s cash, cash equivalents, and marketable securities amounted to $625.7 million during the quarter. The management anticipates that this will fund the firm’s operations into 2027.

Arcellx Inc. (NASDAQ:ACLX) is advancing toward full production of its lead product, anito-cel, with promising Phase 2 data showing a 97% overall response rate and 62% complete response rate for relapsed or refractory multiple myeloma (RRMM), supporting its planned 2026 commercial launch. The firm is also developing cell therapies for acute myeloid leukemia and generalized myasthenia gravis. Additionally, recent board appointments of Andrew Galligan, with financial expertise, and Kristin Myers, with operational experience, are expected to bolster the success of anito-cel’s launch.